We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of DPP-4 Inhibitors.
- Authors
Nam Hoon Kim; Sin Gon Kim
- Abstract
During past several years, a novel class of antihyperglycemic agents, dipeptidyl peptidase-4 (DPP-4) inhibitors, has become one of the most important options in the management of type 2 diabetes. These agents have unique insulinotropic actions as well as other advantages such as lower hypoglycemia and a weight-neutral effect compared to traditional insulin secretagogues. To date, 6 different DPP-4 inhibitors have been introduced: sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin and gemiglitin. This review provides a summary of the clinical data for each DPP-4 inhibitor, and discusses the similarities and differences between them
- Subjects
CD26 antigen; TYPE 2 diabetes; HYPOGLYCEMIA; SITAGLIPTIN; INCRETINS
- Publication
Journal of Korean Diabetes, 2013, Vol 14, Issue 3, p111
- ISSN
2233-7431
- Publication type
Academic Journal
- DOI
10.4093/jkd.2013.14.3.111